These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 16880719

  • 1. [Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease].
    Takatori Y.
    Yakugaku Zasshi; 2006 Aug; 126(8):607-16. PubMed ID: 16880719
    [Abstract] [Full Text] [Related]

  • 2. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons.
    Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, Akaike A.
    J Pharmacol Exp Ther; 2003 Aug; 306(2):772-7. PubMed ID: 12734391
    [Abstract] [Full Text] [Related]

  • 3. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade.
    Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A.
    Neuropharmacology; 2006 Sep; 51(3):474-86. PubMed ID: 16762377
    [Abstract] [Full Text] [Related]

  • 4. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation.
    Takada-Takatori Y, Kume T, Izumi Y, Ohgi Y, Niidome T, Fujii T, Sugimoto H, Akaike A.
    Biol Pharm Bull; 2009 Mar; 32(3):318-24. PubMed ID: 19252271
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil.
    Takada-Takatori Y, Kume T, Ohgi Y, Izumi Y, Niidome T, Fujii T, Sugimoto H, Akaike A.
    J Neurosci Res; 2008 Dec; 86(16):3575-83. PubMed ID: 18655200
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of neuroprotective effects of nicotine and acetylcholinesterase inhibitors: role of alpha4 and alpha7 receptors in neuroprotection.
    Akaike A, Takada-Takatori Y, Kume T, Izumi Y.
    J Mol Neurosci; 2010 Jan; 40(1-2):211-6. PubMed ID: 19714494
    [Abstract] [Full Text] [Related]

  • 7. Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons.
    Kume T, Sugimoto M, Takada Y, Yamaguchi T, Yonezawa A, Katsuki H, Sugimoto H, Akaike A.
    Eur J Pharmacol; 2005 Dec 19; 527(1-3):77-85. PubMed ID: 16313899
    [Abstract] [Full Text] [Related]

  • 8. Neuroprotective effects of galanthamine and tacrine against glutamate neurotoxicity.
    Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Niidome T, Sugimoto H, Fujii T, Okabe S, Akaike A.
    Eur J Pharmacol; 2006 Nov 07; 549(1-3):19-26. PubMed ID: 16996497
    [Abstract] [Full Text] [Related]

  • 9. Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death.
    Noh MY, Koh SH, Kim Y, Kim HY, Cho GW, Kim SH.
    J Neurochem; 2009 Mar 07; 108(5):1116-25. PubMed ID: 19077054
    [Abstract] [Full Text] [Related]

  • 10. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.
    Arias E, Gallego-Sandín S, Villarroya M, García AG, López MG.
    J Pharmacol Exp Ther; 2005 Dec 07; 315(3):1346-53. PubMed ID: 16144975
    [Abstract] [Full Text] [Related]

  • 11. Study of neuroprotection of donepezil, a therapy for Alzheimer's disease.
    Akasofu S, Kimura M, Kosasa T, Sawada K, Ogura H.
    Chem Biol Interact; 2008 Sep 25; 175(1-3):222-6. PubMed ID: 18571635
    [Abstract] [Full Text] [Related]

  • 12. Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation.
    Akasofu S, Kosasa T, Kimura M, Kubota A.
    Eur J Pharmacol; 2003 Jul 04; 472(1-2):57-63. PubMed ID: 12860473
    [Abstract] [Full Text] [Related]

  • 13. Preclinical evidence of neuroprotection by cholinesterase inhibitors.
    Akaike A.
    Alzheimer Dis Assoc Disord; 2006 Jul 04; 20(2 Suppl 1):S8-11. PubMed ID: 16772755
    [Abstract] [Full Text] [Related]

  • 14. Neuroprotection by donepezil against glutamate excitotoxicity involves stimulation of alpha7 nicotinic receptors and internalization of NMDA receptors.
    Shen H, Kihara T, Hongo H, Wu X, Kem WR, Shimohama S, Akaike A, Niidome T, Sugimoto H.
    Br J Pharmacol; 2010 Sep 04; 161(1):127-39. PubMed ID: 20718745
    [Abstract] [Full Text] [Related]

  • 15. Acetylcholinesterase inhibition in Alzheimer's Disease.
    Ibach B, Haen E.
    Curr Pharm Des; 2004 Sep 04; 10(3):231-51. PubMed ID: 14754384
    [Abstract] [Full Text] [Related]

  • 16. Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors.
    Li W, Pi R, Chan HH, Fu H, Lee NT, Tsang HW, Pu Y, Chang DC, Li C, Luo J, Xiong K, Li Z, Xue H, Carlier PR, Pang Y, Tsim KW, Li M, Han Y.
    J Biol Chem; 2005 May 06; 280(18):18179-88. PubMed ID: 15710623
    [Abstract] [Full Text] [Related]

  • 17. Donepezil attenuates excitotoxic damage induced by membrane depolarization of cortical neurons exposed to veratridine.
    Akasofu S, Sawada K, Kosasa T, Hihara H, Ogura H, Akaike A.
    Eur J Pharmacol; 2008 Jul 07; 588(2-3):189-97. PubMed ID: 18508044
    [Abstract] [Full Text] [Related]

  • 18. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.
    Kim SH, Kandiah N, Hsu JL, Suthisisang C, Udommongkol C, Dash A.
    Br J Pharmacol; 2017 Dec 07; 174(23):4224-4232. PubMed ID: 28901528
    [Abstract] [Full Text] [Related]

  • 19. The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
    Stahl SM.
    J Clin Psychiatry; 2000 Oct 07; 61(10):710-1. PubMed ID: 11078030
    [Abstract] [Full Text] [Related]

  • 20. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.
    Drugs Aging; 2004 Oct 07; 21(7):453-78. PubMed ID: 15132713
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.